(Total Views: 322)
Posted On: 04/14/2021 12:31:42 PM
Post# of 36564
The press release said: "Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) ("Generex" or the "Company"
, an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative "Complete Vaccine" to fight SARS-CoV-2, today announced the company has submitted a response package to the FDA's comments in their Pre-IND Written Response." Emphasis on "has submitted." So, on what basis do you continue to say "with it still pending to be submitted?"
, an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative "Complete Vaccine" to fight SARS-CoV-2, today announced the company has submitted a response package to the FDA's comments in their Pre-IND Written Response." Emphasis on "has submitted." So, on what basis do you continue to say "with it still pending to be submitted?"
(0)
(0)
